Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab.

Trial Profile

Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 19 May 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 17 Nov 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 25 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top